Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Cisplatin-Irinotecan and Chemoradiotherapy in Esophageal Carcinoma
NCT00590031Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2002
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and irinotecan in esophageal carcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Pathologic Complete Response at 2 years. Started Nov 2002; status: completed.
02
Drugs
cisplatinirinotecan
03
Conditions
esophageal carcinoma
Beyond the preview
Go deeper on NCT00590031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00590031.